Discussion on the Issues and Countermeasures in Clinical Trial Insurance
10.12026/j.issn.1001-8565.2017.03.17
- VernacularTitle:浅析临床试验保险中的问题及对策
- Author:
Peng PENG
;
Weian YUAN
;
Yihui HU
;
Jie TANG
;
Leilei ZHU
;
Min HE
;
Jian JIANG
- Keywords:
Clinical Trial;
Insurance;
Risk Control
- From:
Chinese Medical Ethics
2017;30(3):328-330,335
- CountryChina
- Language:Chinese
-
Abstract:
Through analyzing the current situation and coverage controversy of Chinese clinical trial insurance,this paper stated that the attending insurance rate in domestic clinical trials was entirely low.The sponsors,clinical trial institutions,investigators and insurance companies paid attention of different levels to clinical trial insurance.Therefore,the risk awareness of drug/medical device clinical trials should be enhanced.It is necessary to give impetus to clinical trial insurance system,during which all parties need to make a joint effort including government departments,ethics committees,sponsors,clinical trial institutions,investigators and insurance companies.
